Sec Form 13G Filing - John D. Halpern filing for Eterna Therapeutics Inc. (ERNA) - 2025-02-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Share counts in Rows 6, 8, and 9 represents (i) 5,136,571 shares of common stock, par value $0.005 per share (the "Common Stock") of Eterna Therapeutics Inc., a Delaware corporation (the "Issuer") held by the John D. Halpern Revocable Trust (the "Trust"), a trust of which John D. Halpern and Katherine H. Halpern are trustees; and (ii) 10 shares of Common Stock of the Issuer (the "Warrant Shares") issuable upon exercise of that certain Pre-Funded Common Stock Purchase Warrant, in substantially the form as the form of Warrant filed as Exhibit 10.3 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 29, 2024 (the "Warrant"), issued by the Issuer in favor of the Trust which may be exercised at any time, at a nominal exercise price of $0.005 per Warrant Share.Pursuant to the terms of the Warrant, the Reporting Person cannot exercise the Warrant for Warrant Shares to the extent the Reporting Person would beneficially own, after any such conversion or exercise, more than 9.99% of the outstanding shares of Common Stock (the "Blocker"). The table excludes 114,990 shares of Common Stock issuable upon exercise of the Warrant because of the Blocker.Percentage of ownership in Row 11 is based on an aggregate of 51,374,723 shares of Common Stock outstanding, which is derived from: (i) 51,374,713 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024; plus (ii) the 10 Warrant Shares issuable upon exercise of the Warrant within 60 days, which are deemed outstanding pursuant to Rule 13d-3(d)(1)(i) of the Securites Exchange Act of 1934, as amended.


SCHEDULE 13G



Comment for Type of Reporting Person:  As noted above, Share counts in Rows 6, 8, and 9 represents (i) 5,136,571 shares of Common Stock of the Issuer held by the Trust, of which John D. Halpern and Katherine H. Halpern are trustees; and (ii) 10 shares of the Warrant Shares issuable upon exercise of the Warrant.Also as noted above, the Warrant has a Blocker and the table excludes 114,990 shares of Common Stock issuable upon exercise of the Warrant because of the Blocker.Percentage of ownership in Row 11 is based on an aggregate of 51,374,723 shares of Common Stock outstanding, which is derived from: (i) 51,374,713 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024; plus (ii) the 10 Warrant Shares issuable upon exercise of the Warrant within 60 days, which are deemed outstanding pursuant to Rule 13d-3(d)(1)(i) of the Securites Exchange Act of 1934, as amended.


SCHEDULE 13G


 
John D. Halpern
 
Signature:/s/ John D. Halpern
Name/Title:John D. Halpern
Date:02/14/2025
 
Katherine H. Halpern
 
Signature:/s/ Katherine H. Halpern
Name/Title:Katherine H. Halpern
Date:02/14/2025
primary_doc.xml